Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, global market expansion, and strategic pipeline developments. Despite some uncertainties in pricing and compliance, the overall sentiment is positive due to strong revenue growth, operational efficiency, and a well-positioned cash reserve. The Q&A section reinforces this with management's confidence in global demand and strategic focus on pipeline investment. The absence of immediate stock buybacks is offset by the promising outlook on market expansion and product adoption, suggesting a positive stock price movement.
Key Financial Performance
Net VYJUVEK Revenue (Q4 2025) $107.1 million, an increase of approximately 18% year-over-year. The growth was driven by contributions from Europe and Japan as the company builds momentum in its initial overseas markets.
Total Net VYJUVEK Revenue (since launch) Over $730 million. This figure reflects the cumulative revenue generated since the product's launch.
Gross Margin (Q4 2025) 94%, compared to 95% in Q4 2024. The slight decrease is attributed to the higher cost per unit for products sold outside the U.S. ahead of planned manufacturing process optimizations.
Year-to-Date VYJUVEK Net Revenue (2025) $389.1 million, an increase of approximately 34% compared to full year 2024 revenue. The growth was attributed to strong demand and expanded global sales.
Cost of Goods Sold (Q4 2025) $6.6 million, compared to $4.9 million in Q4 2024. The increase is due to the volume of products sold outside the U.S., which carry a higher cost per unit.
R&D Expenses (Q4 2025) $14.8 million, compared to $13.5 million in Q4 2024. The increase is due to ongoing development efforts and pipeline advancements.
SG&A Expenses (Q4 2025) $41.4 million, compared to $31.3 million in Q4 2024. The increase is primarily due to higher headcount, legal and consulting services, and marketing costs to support global launches.
Net Income (Q4 2025) $51.4 million, representing $1.77 per basic share and $1.70 per diluted share. This reflects strong revenue growth and operational efficiency.
Net Income (Full Year 2025) $204.8 million, representing $7.08 per basic share and $6.84 per diluted share. This includes one-time noncash tax benefits.
Cash and Investments (End of 2025) $955.9 million. This positions the company well to support global commercial launches and pipeline milestones.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VYJUVEK: Launched in Europe and Japan, with over 90 DEB patients prescribed across Germany, France, and Japan. Home administration is now possible, reducing patient burden. Recognized with the Prix Galien in France for innovation.
KB407: Successful delivery and expression of full-length wild-type CFTR protein in cystic fibrosis patients. Preparing for repeat dosing study in 2026.
KB801 and KB803: Updated protocols for flexible administration options, including home dosing. Data readouts expected by year-end.
KB111: Fast Track designation received for Hailey-Hailey disease treatment. Registrational study to start in the second half of 2026.
KB408: Progressing in repeat dosing study for AATD lung disease. Data update expected by year-end.
KB707: RMAT designation received for advanced NSCLC treatment. Clinical data updates expected later this year.
Geographic Expansion: Distributor agreements signed in over 20 countries, aiming for 40+ by 2026. Italy launch planned for the second half of 2026. Strong demand in Europe and Japan.
Pricing Negotiations: Ongoing in Germany and France, expected to conclude by 2026-2027. Successful pricing negotiation completed in Japan.
U.S. Market: Reimbursement approvals accelerating, with over 660 approvals since launch. Expanded sales force and over 500 unique prescribers reached.
Revenue Growth: Q4 2025 VYJUVEK revenue at $107.1 million, total revenue since launch over $730 million. Gross margin at 94%.
Operational Efficiency: Improved patient identification and expanded prescriber base in the U.S. Manufacturing optimizations planned for international markets.
Pipeline Development: Focused on advancing multiple registrational programs and leveraging HSV-1 platform for gene delivery.
Capital Allocation: Disciplined investment in measurable milestones, aiming for value compounding without dilution.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Pricing negotiations in Germany and France: Ongoing pricing negotiations in Germany and France are expected to continue until at least the second half of 2026 in Germany and 2027 in France. This could delay revenue realization and create uncertainty in financial planning.
Regulatory hurdles in Japan: Strict regulations regarding the handling of gene therapies in Japan require a unique in-country distribution model, which adds complexity and potential delays to operations.
Supply chain and manufacturing costs: The cost of goods sold for products outside the U.S. remains higher due to the need for planned manufacturing process optimizations, which could impact gross margins.
Evolving utilization patterns in the U.S.: Some longer-tenured patients in the U.S. are shifting toward more intermittent treatment cycles, which may affect revenue growth and demand predictability.
Geographic expansion challenges: The company is expanding into over 40 countries by 2026, but this rapid expansion could strain resources and operational capabilities.
Clinical trial risks: The company is conducting multiple registrational trials and updates to protocols, which carry inherent risks of delays, regulatory challenges, or failure to meet endpoints.
Economic uncertainties in Europe: Ongoing pricing negotiations and economic conditions in Europe could impact the company's ability to secure favorable pricing and reimbursement terms.
Patient and caregiver training for self-administration: The shift to self-administration for some treatments requires effective training programs to mitigate risks of human error, which could impact treatment outcomes and patient safety.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects overseas expansion to be the predominant driver of revenue growth in 2026, with a focus on Europe and Japan. Italy is expected to launch in the second half of 2026.
Gross Margins: Gross margins are expected to remain in the 90% to 95% range for the foreseeable future.
Pipeline Development: The company plans to initiate repeat dosing for KB407 in the first half of 2026 and expects data readouts for KB801, KB803, and KB408 before the end of the year. Registrational studies for KB111 and KB707 are also planned for 2026.
Global Expansion: Pricing negotiations in Germany and France are expected to continue until at least the second half of 2026 and 2027, respectively. The company has expanded its distributor network to include Israel and plans to finalize pricing and launch in Italy in the second half of 2026.
Operational Expenses: Non-GAAP R&D and SG&A expenses for 2026 are anticipated to be approximately $175 million to $195 million, reflecting increased spending on global launches and pipeline development.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On VYJUVEK, any visibility into the 1Q and looking ahead to 2026, particularly contribution from ex U.S. versus the U.S. on the dollar value?
A:Krish Krishnan stated that while the predominant growth driver will be from ex U.S., demand in the U.S. is accelerating. He mentioned that reimbursement approvals in the U.S. are up quarter-over-quarter, but patient start-stop regimes make predictions nuanced. In Europe, the launch is recent and is an accelerating growth driver. The company plans to break down U.S. versus ex U.S. revenue in the 1Q report.
Q:Why was the dosing regimen for both ocular and NK adjusted to be more frequent? Any data to support this change?
A:Suma Krishnan explained that the weekly dose for 801 was deliberate and based on blinded data. The change to home administration was made for commercial viability and to avoid human error in dosing. The daily dose is easier for patients to remember and ensures compliance. The drug has a safe profile, and the change was made to optimize dosing for patients.
Q:Can you provide insight into the compliance rate in the EU and Japan? Also, any updates on stock buyback options versus pipeline investment or M&A?
A:Krish Krishnan noted that compliance in Europe is similar to the U.S. during its early launch. In Japan, patients face a 2-week prescription renewal requirement in the first year, which may impact compliance temporarily. Regarding stock buybacks, the company is focused on its pipeline and larger indications, and does not plan to use cash for in-licensing or acquisitions at the moment.
Q:What is the status of pricing negotiations in France, Germany, and Japan?
A:Krish Krishnan stated that pricing agreements in Germany are expected in 3Q or 4Q of this year, while France's pricing agreement is likely to shift to the first half of next year. Japan already has a price, and accruals will be made in Germany and France until pricing is finalized.
Q:What updates can you provide on the ophthalmology studies and the modified dosing regimens?
A:Suma Krishnan mentioned that the powering and number of patients in the studies have not changed. The company is targeting 30 sites for enrollment and expects to complete enrollment by the end of the year. The modified dosing regimens were based on lessons learned from VYJUVEK and aim to provide flexibility and convenience for patients.
Q:Can you provide details on the 90 patients prescribed VYJUVEK in Europe and the cadence of patient additions?
A:Krish Krishnan explained that the 90-patient estimate is based on vials shipped and pharmacy disclosures, making it an approximation. Segmenting this number by country is not precise. The estimate provides directional guidance until revenues are broken out in 1Q.
Q:How does reimbursement work in Italy compared to Germany and France?
A:Krish Krishnan stated that Italy will launch once pricing is finalized, avoiding an accrual situation. This differs from Germany and France, where accruals are made until pricing is definitive.
Q:Was patient compliance a major factor in getting at-home self-dosing for 803 in ocular DEB? Why was the dosing schedule set to three times a week for 803 and once daily for 801?
A:Suma Krishnan confirmed that home administration and patient convenience were key factors. The three-times-a-week schedule for 803 provides flexibility, while the once-daily schedule for 801 ensures compliance. Both regimens were based on prior data and patient feedback.
Q:What happens to the data generated under prior dosing regimens in the ocular studies? Were there changes to the PFU or volume of dose?
A:Suma Krishnan clarified that the dose and PFU remain unchanged. Data from prior regimens contribute to safety analysis, and the final protocol and statistical analysis plan have been agreed upon with the agency. All future enrollments will follow the modified regimen.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the geographic breakdown of the 90 patients prescribed VYJUVEK in Europe, citing differences in laws and the approximation of patient numbers. Additionally, they did not provide a definitive timeline for stock buybacks, citing uncertainties in larger indications and partnerships.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AP
CFTR
Class
EMERALD
France Japan
HCP caregiver
Italy
Patients
RD SGA
SGA increase
access patient
breakthrough
caregiver patient
center excellence
colleague
commitment
community setting
delivery
demand
designation KB
epidermolysis bullosa
gene
geography
home setting
medicine home
modulator patient
momentum
negotiation Germany
network
patient training
placebo HCP
potential program
pricing negotiation
process
protocol
setting patient
study patient
transduction
trial
KRYS Transcript
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Positive5-4
The earnings call highlights strong financial performance, with significant net income and EPS growth, and a robust cash position. The Q&A session indicates positive global market trends and strategic pipeline developments. Despite some management ambiguity, the overall sentiment is optimistic, supported by strong ex-U.S. growth, positive KB803 launch expectations, and successful at-home administration of VYJUVEK. These factors suggest a positive stock price movement over the next two weeks.
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Positive2-17
The earnings call highlights strong financial performance, global market expansion, and strategic pipeline developments. Despite some uncertainties in pricing and compliance, the overall sentiment is positive due to strong revenue growth, operational efficiency, and a well-positioned cash reserve. The Q&A section reinforces this with management's confidence in global demand and strategic focus on pipeline investment. The absence of immediate stock buybacks is offset by the promising outlook on market expansion and product adoption, suggesting a positive stock price movement.
Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
KRYS Slides
KRYS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
